- New Barcelona site to help drive global expansion of
QIAstat-Dx as QIAGEN expands local presence with multi-year
investment
- Site in Esplugues de Llobregat to serve as an innovation hub
for QIAstat-Dx, supporting the development of infectious disease
tests and precision medicine applications
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced plans to move its QIAstat-Dx operations within the
Barcelona area to a new site in Esplugues de Llobregat as part of a
multi-year investment to strengthen this business.
Set to open in early 2026, the new site will cover the entire
value chain for the QIAstat-Dx system, which is used for syndromic
testing to identify the cause of an illness – especially in the
areas of respiratory, gastrointestinal and meningitis /
encephalitis conditions.
QIAstat-Dx is also being developed for use in precision
medicine, in particular to support the expansion of recent
partnerships announced with Eli Lilly and AstraZeneca. In precision
medicine applications, QIAstat‑Dx for instance enables specialty
care providers to perform genotyping whilst patients undergo
routine clinical examination, thus enabling fast decision-making
for potential suitability for certain genomically targeted
medicines.
The new site builds on the long-standing presence of QIAGEN in
the Barcelona area. Teams at the site will include Research &
Development, Manufacturing, Sales, Marketing, Quality Assurance and
Regulatory Affairs. In addition, it will serve as a center of
excellence for R&D in microfluidics, as well as system and
assay development.
“QIAstat-Dx demonstrated its value during the COVID-19 pandemic,
supporting healthcare providers with rapid syndromic testing and
crucial information when time mattered most,” said Thierry Bernard,
CEO of QIAGEN. “Now we are building on this success by expanding
the QIAstat-Dx pipeline to address a broader spectrum of healthcare
needs. This means both expanding the range of pathogens for
infectious disease testing as well as developing solutions for
other disease areas and precision medicine applications.”
Barcelona provides an ideal location for this expansion,
combining access to scientific talent with a robust ecosystem that
includes universities, research institutions, start-ups, and well
established pharma and life science companies.
QIAGEN can also build on the local expertise in the QIAstat-Dx
technology, which was originally developed by a start-up from
Barcelona and acquired by QIAGEN in 2018.
The Esplugues de Llobregrat site will enable QIAGEN to advance
diagnostic capabilities in infectious diseases and beyond, helping
to meet the growing demand for rapid diagnostics in diverse
healthcare settings, from hospitals and clinics to decentralized
testing points. The site will span 8,000 square meters and include
offices, manufacturing lines, clean rooms, laboratories and
logistics areas. The base building of the new facility has received
LEED Platinum Certification, the highest standard in
energy-efficient and environmentally responsible building design.
The fit-out of the new facility will also meet this high standard
and will be equipped with digitalized production lines.
The QIAstat-Dx system, designed for laboratory use, employs
cost-efficient, single-use cartridges with built-in sample
processing and on-board reagents. Utilizing multiplex real-time
PCR, it detects and differentiates between multiple genetic
targets, with results in about an hour. QIAstat-Dx also provides
easy‑to‑view cycle threshold (Ct) values and amplification curves,
offering additional insights not available with end-point PCR or
other techniques.
Four QIAstat-Dx panels have been cleared by the U.S. Food and
Drug Administration (FDA), including panels for pathogens causing
respiratory and gastrointestinal infections, meningitis and
encephalitis. In the European Union and other countries that accept
the marking, two panels for detecting respiratory and
gastrointestinal infections have received CE-marking under the new
In-Vitro Diagnostic Medical Devices Regulation (IVDR).
The system already has a strong footprint in infectious disease
testing and will be further strengthened by accelerating
innovations and expanding the testing menu to a broader range of
pathogens, such as blood culture identification and complicated
urinary tract infections
QIAGEN has already signed three partnerships with pharma
companies including Eli Lilly and AstraZeneca to expand QIAstat‑Dx
beyond infectious diseases. The new facilities will support this
expansion into other disease areas such as neurodegenerative,
metabolic, inflammatory and other genetically driven chronic
diseases.
For more information on QIAstat-Dx visit
https://www.qiagen.com/de-us/applications/syndromic-testing.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare) and
Life Sciences (academia, pharma R&D and industrial
applications, primarily forensics). As of September 30, 2024,
QIAGEN employed more than 5,800 people in over 35 locations
worldwide. Further information can be found at
https://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, timing for launch and development, marketing
and/or regulatory approvals, financial and operational outlook,
growth and expansion, collaborations, markets, strategy or
operating results, including without limitation its expected
adjusted net sales and adjusted diluted earnings results, are
forward-looking, such statements are based on current expectations
and assumptions that involve a number of uncertainties and risks.
Such uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses; actions of governments, global or regional economic
developments, weather or transportation delays, natural disasters,
political or public health crises, and its impact on the demand for
our products and other aspects of our business, or other force
majeure events; as well as the possibility that expected benefits
related to recent or pending acquisitions may not materialize as
expected; and the other factors discussed under the heading “Risk
Factors in our most recent Annual Report on Form 20-F. For further
information, please refer to the discussions in reports that QIAGEN
has filed with, or furnished to, the U.S. Securities and Exchange
Commission.
Source: QIAGEN N.V.
Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241128928344/en/
QIAGEN: Investor Relations John Gilardi, +49 2103
29 11711 Domenica Martorana, +49 2103 29 11244 e-mail:
ir@QIAGEN.com Public Relations Thomas Theuringer, +49 2103
29 11826 Lisa Specht, +49 2103 29 14181 e-mail: pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
